How much does a box of Naxitamab injection cost?

Naxitamab injection (Naxitamab) is an anti-GD2 monoclonal antibody. GD2 is a suitable antigen for monoclonal antibody therapy because it is highly expressed, with 5-10 million copies per neuroblastoma cell. Furthermore, its expression is stable, with little evidence of reduced response to immunotherapy directed against this substance. GD2 is a tumor antigen, which means that its expression in normal tissues is essentially restricted to fetal development, mature neurons, and pain-conducting fibers of the peripheral nervous system. In children and adults, most GD2-expressing neurons are protected by the blood-brain barrier from intravenous infusion of anti-GD2 antibodies.

Nasitumumab injection, sold in the United States under the trademark Danyelza, has been approved in combination with GM-CSF for the treatment of patients with refractory or relapsed neuroblastoma of the bone or bone marrow who have had a partial response or stable disease to prior therapy. This FDA indication was approved through an expedited regulatory process that is based on demonstrated objective response and significant duration of response. On an outpatient basis, patients were administered nascituzumab injection three times a week, with treatment repeated every four weeks. Nasitumumab injection obtained priority review from the FDA and was designated as an "Orphan Drug", "Breakthrough Therapy" and "Rare Pediatric Disease Designation".

It is understood that noxituzumab injection has been approved in China, but it has not been included in medical insurance. Its price is still unclear and the purchase method is difficult. The original drug of Naxituzumab injection marketed overseas is very expensive, and the price may fluctuate due to exchange rates. For more drug information and specific prices, please consult a medical consultant.